Stocks Health care IDXX
NASDAQ · Health careIdexx Laboratories Inc (IDXX)
Idexx Laboratories Inc brought in $4.7B of revenue over the twelve months to September 30, 2026, up 11.9% from a year earlier. Net income was $1.2B, a net margin of 25.4%. Operating cash flow minus capital spending left $1.1B of free cash flow in fiscal 2025. At September 30, 2026 it held $197.5M in cash against $374.9M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 2, 2026.
Key facts about Idexx Laboratories Inc
- Net worth
- Idexx Laboratories Inc has a market value (market cap) of $54.1B at the latest share price, and shareholders' equity of $1.9B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $4.3B (+10.4% year on year), with net income of $1.1B. Over the 12 months to September 30, 2026: revenue $4.7B, net income $1.2B.
- Cash flow
- In fiscal 2025 operations brought in $1.2B of cash; after $124.7M of capital spending, free cash flow was $1.1B.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 2, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Idexx Laboratories Inc's next report is expected around February 1, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Idexx Laboratories Inc does
IDEXX Laboratories develops, manufactures, and distributes diagnostic products and services for companion animals, livestock, and poultry. It also provides water microbiology testing systems and dairy testing services to veterinarians, livestock producers, and water testing laboratories. Its shares trade on NASDAQ under the ticker IDXX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $4.3B | $1.1B | $13.08 | $1.1B |
| 2024 | $3.9B | $887.9M | $10.67 | $808.1M |
| 2023 | $3.7B | $845M | $10.06 | $772.9M |
| 2022 | $3.4B | $679.1M | $8.03 | $394.1M |
| 2021 | $3.2B | $744.8M | $8.60 | $636M |
| 2020 | $2.7B | $581.8M | $6.71 | $541.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where IDXX ranks in Health care
Latest SEC filings
What Idexx Laboratories Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 2, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 9.9% to $1.2B versus the same quarter last year; diluted EPS $4.01 versus $3.40.
- November 2, 2026
- October 30, 2026Passive stake (5% or more) SCHEDULE 13G
- August 4, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 9.7% to $1.2B versus the same quarter last year; diluted EPS $4.27 versus $3.63.
- August 4, 2026
- June 1, 2026
- May 15, 2026
- May 5, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 14% to $1.1B versus the same quarter last year; diluted EPS $3.47 versus $2.96.
- May 5, 2026
- April 30, 2026Passive stake (5% or more) SCHEDULE 13G
What is IDXX worth? A DCF from its reported cash flow
Insider trades
What the people running Idexx Laboratories Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $28.6M worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 4, 2026 | Junius Daniel MDirector | Sold | 700 | $494K |
| November 4, 2026 | Junius Daniel MDirector | Sold | 500 | $350.8K |
| November 4, 2026 | Lane MichaelExecutive Vice President | Sold | 243 | $167.1K |
| November 4, 2026 | Lane MichaelExecutive Vice President | Sold | 2,059 | $1.4M |
| November 4, 2026 | Lane MichaelExecutive Vice President | Sold | 1,677 | $1.2M |
| November 4, 2026 | Mazelsky Jonathan JayExecutive Chair of the Board, Director | Exercised options | 25,140 | $4.5M |
| November 4, 2026 | Mazelsky Jonathan JayExecutive Chair of the Board, Director | Sold | 1,945 | $1.4M |
| November 4, 2026 | Mazelsky Jonathan JayExecutive Chair of the Board, Director | Sold | 4,075 | $2.8M |
Who owns IDXX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Vanguard Capital Management13G, passive | 7.51% | April 30, 2026 |
| Vanguard Portfolio Management13G, passive | 5.04% | October 30, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 1,300 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 8,170,178 | -195,375 |
| Vanguard Capital Management LLC | 5,152,213 | -30,294 |
| Vanguard Portfolio Management LLC | 3,896,521 | -14,342 |
| State Street Corp | 3,748,660 | +74,475 |
| Invesco Ltd. | 3,611,416 | +261,739 |
| Geode Capital Management, LLC | 2,562,886 | -98,113 |
| Bamco Inc | 1,976,778 | +343,411 |
| Morgan Stanley | 1,356,103 | +40,149 |
| Bank of New York Mellon Corp | 1,193,343 | -311,189 |
| Arrowstreet Capital, Limited Partnership | 1,067,078 | +228,239 |
| Fundsmith LLP | 1,019,887 | -445,899 |
| Blair William & Co | 918,556 | -27,780 |
| Northern Trust Corp | 918,137 | +6,244 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 911,489 | +39,700 |
| Fmr LLC | 822,643 | +539,667 |
| American Century Companies Inc | 808,358 | +208,427 |
| Capital Research Global Investors | 789,111 | +7,766 |
| Jpmorgan Chase & Co | 755,791 | -24,091 |
| Principal Financial Group Inc | 743,246 | -137,943 |
| Goldman Sachs Group Inc | 738,708 | +21,787 |
Insiders
16 insiders reported holding 165,004 shares in total, about $113.3M at the last price.
| Holder | Shares |
|---|---|
| Mazelsky Jonathan JayExecutive Chair of the Board, Director | 83,803 |
| Hunt NimrataExecutive Vice President | 18,141 |
| Erickson Michael GExecutive Vice President | 15,092 |
| Fennell GeorgeExecutive Vice President | 10,433 |
| Kingsley Lawrence DDirector | 9,568 |
| Underberg Sharon E.EVP, GC & Corporate Secretary | 7,169 |
| Emerson AndrewEVP, CFO and Treasurer | 4,421 |
| Lane MichaelExecutive Vice President | 4,076 |
| Schreck MichaelExecutive Vice President | 3,089 |
| Johnson Michael PerkinsExecutive Vice President | 2,795 |
Questions about IDXX
What does Idexx Laboratories Inc do?
IDEXX Laboratories develops, manufactures, and distributes diagnostic products and services for companion animals, livestock, and poultry. It also provides water microbiology testing systems and dairy testing services to veterinarians, livestock producers, and water testing laboratories. Its shares trade on NASDAQ under the ticker IDXX.
What is Idexx Laboratories Inc's net worth?
Idexx Laboratories Inc has a market value (market cap) of $54.1B at the latest share price, and shareholders' equity of $1.9B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Idexx Laboratories Inc profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $1.2B on revenue of $4.7B, a net margin of 25.4%.
How much revenue does Idexx Laboratories Inc make?
Over the twelve months to September 30, 2026 Idexx Laboratories Inc reported revenue of $4.7B. That is 11.9% more than a year earlier.
When did Idexx Laboratories Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 2, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 5, 2026.
When is Idexx Laboratories Inc's next earnings report?
Idexx Laboratories Inc's next report is expected around February 1, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare IDXX with
Follow IDXX
Get an email when Idexx Laboratories Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Idexx Laboratories Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.